Clinical Trial Update: STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for STIMEP evaluating subthalamic nucleus stimulation in patients with drug-resistant epilepsy; the Phase 2/3 study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-resistant Epilepsy
• Epilepsy

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Epilepsy, Drug Resistant | Phase 2, Phase 3 | Status: TERMINATED